Terms: = Prostate cancer AND SMAD4, JIP, Q13485, 4089, ENSG00000141646, MADH4, DPC4 AND Diagnosis
11 results:
1. Racial and Ethnic Disparities in the Use of prostate Magnetic Resonance Imaging Following an Elevated prostate-Specific Antigen Test.
Abashidze N; Stecher C; Rosenkrantz AB; Duszak R; Hughes DR
JAMA Netw Open; 2021 Nov; 4(11):e2132388. PubMed ID: 34748010
[TBL] [Abstract] [Full Text] [Related]
2. prostate cancer screening: what do men know, think and do about their risk? exploring the opinions of men in an urban area in Lagos State, Nigeria: a mixed methods survey.
Ugochukwu UV; Odukoya OO; Ajogwu A; Ojewola RW
Pan Afr Med J; 2019; 34():168. PubMed ID: 32153708
[TBL] [Abstract] [Full Text] [Related]
3. Impact of 5α-reductase inhibitor and α-blocker therapy for benign prostatic hyperplasia on prostate cancer incidence and mortality.
Van Rompay MI; Curtis Nickel J; Ranganathan G; Kantoff PW; Solomon KR; Lund JL; McKinlay JB
BJU Int; 2019 Mar; 123(3):511-518. PubMed ID: 30216624
[TBL] [Abstract] [Full Text] [Related]
4. Evaluating a 4-marker signature of aggressive prostate cancer using time-dependent AUC.
Gerke TA; Martin NE; Ding Z; Nuttall EJ; Stack EC; Giovannucci E; Lis RT; Stampfer MJ; Kantoff PW; Parmigiani G; Loda M; Mucci LA
Prostate; 2015 Dec; 75(16):1926-33. PubMed ID: 26469352
[TBL] [Abstract] [Full Text] [Related]
5. prostate-specific antigen velocity is not better than total prostate-specific antigen in predicting prostate biopsy diagnosis.
Gorday W; Sadrzadeh H; de Koning L; Naugler CT
Clin Biochem; 2015 Dec; 48(18):1230-4. PubMed ID: 26164541
[TBL] [Abstract] [Full Text] [Related]
6. prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, Despite no recommendations for PSA screening: results from a population-based study, 2003-2011.
Nordström T; Aly M; Clements MS; Weibull CE; Adolfsson J; Grönberg H
Eur Urol; 2013 Mar; 63(3):419-25. PubMed ID: 23083803
[TBL] [Abstract] [Full Text] [Related]
7. Reevaluation and identification of the best immunohistochemical panel (pVHL, Maspin, S100P, IMP-3) for ductal adenocarcinoma of the pancreas.
Liu H; Shi J; Anandan V; Wang HL; Diehl D; Blansfield J; Gerhard G; Lin F
Arch Pathol Lab Med; 2012 Jun; 136(6):601-9. PubMed ID: 22646265
[TBL] [Abstract] [Full Text] [Related]
8. [Apoptosis in pathologic prostatic processes].
Kruslin B
Acta Med Croatica; 2009 Oct; 63 Suppl 2():49-52. PubMed ID: 19999547
[TBL] [Abstract] [Full Text] [Related]
9. Lower urinary tract symptoms affect one-third of men in a prostate cancer screening population.
Walz J; Suardi N; Hutterer GC; Perrotte P; Gallina A; Bénard F; Valiquette L; McCormack M; Graefen M; Montorsi F; Karakiewicz PI
J Endourol; 2008 Feb; 22(2):369-76. PubMed ID: 18294044
[TBL] [Abstract] [Full Text] [Related]
10. Baseline prevalence of erectile dysfunction in a prostate cancer screening population.
Walz J; Perrotte P; Suardi N; Hutterer G; Jeldres C; Bénard F; Valiquette L; Graefen M; Montorsi F; Karakiewicz PI
J Sex Med; 2008 Feb; 5(2):428-35. PubMed ID: 18086160
[TBL] [Abstract] [Full Text] [Related]
11. Apoptotic regulators in prostatic intraepithelial neoplasia (PIN): value in prostate cancer detection and prevention.
Zeng L; Kyprianou N
Prostate Cancer Prostatic Dis; 2005; 8(1):7-13. PubMed ID: 15477876
[TBL] [Abstract] [Full Text] [Related]
